INFU Stock Analysis
IN
Avoid
Based on Eyestock quantitative analysis, INFU`s fundamental data and valuation indicate an investment grade of Avoid at the current time.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Upside
To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.
Overvalued
InfuSystem Holdings, Inc. engages in the provision of healthcare services. The company is headquartered in Rochester Hills, Michigan and currently employs 420 full-time employees. The company went IPO on 2006-06-15. Its segments include Integrated Therapy Services (ITS) and Durable Medical Equipment Services (DME Services). The ITS segment provides services, such as supplying electronic ambulatory infusion pumps and associated disposable supply kits to private oncology clinics, infusion clinics and hospital outpatient oncology clinics to be utilized in the treatment of a variety of cancers, including colorectal cancer and other disease states (Oncology Business). The DME Services segment’s core service is to sell or rent new and pre-owned pole-mounted and ambulatory infusion pumps and other Durable Medical Equipment; sell treatment-related consumables, and provide biomedical recertification, maintenance and repair services for oncology practices as well as other alternate site settings, including hospitals and pain centers and others.